Verbal Fluencies and Fampridine Treatment in Multiple Sclerosis

Eloi Magnin1, Yoshimasa Sagawa, Ludivine Chamard

  • 1Regional Memory Centre (CMRR), Department of Neurology, University Hospital of Besanx00E7;on, Besanx00E7;on, France.

European Neurology
|December 2, 2015
PubMed
Abstract

Insights

Fampridine may enhance cognitive processing in multiple sclerosis (MS) patients, particularly improving phonological fluency. This effect appears selective and independent of motor improvements in gait.

Area of Science:

  • Neuroscience
  • Clinical Neurology
  • Pharmacology

Background:

  • Fampridine is investigated for cognitive benefits in multiple sclerosis (MS).
  • Motor improvements may confound cognitive assessments.
  • The study aims to isolate fampridine's effects on verbal fluency in MS.

Purpose of the Study:

  • To evaluate the impact of fampridine on verbal phonological and semantic fluencies in MS patients.
  • To determine if fampridine has a selective effect on cognition, independent of motor function.

Main Methods:

  • Prospective, open-label trial with 50 MS patients (EDSS 5.3 ± 1.1).
  • Verbal fluency (phonological and semantic) assessed twice before and twice after fampridine treatment.
  • Gait velocity and fatigue also measured to assess potential confounding factors.

Main Results:

  • Significant improvements in verbal fluencies observed post-fampridine treatment.
  • No correlation found between phonological and semantic fluency improvements.
  • No significant differences in verbal fluency or fatigue between gait responders and non-responders.

Conclusions:

  • Fampridine may offer a selective procognitive benefit, specifically on phonological fluency in MS.
  • This cognitive effect is apparent even in patients who do not show gait improvement.

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.4K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
24